Non-small cell lung cancer(NSCLC)is a malignant tumor with the highest morbidity and mortality rates in China.The emergence of immune checkpoint inhibitors(ICIs)has brought great breakthroughs in NSCLC and has become the standard of care for advanced or early NSCLC without oncogenic driver mutations.However,the status of continuous use of NSCLC immunotherapy in China is obviously insufficient,and there is a large gap between the duration of NSCLC immunotherapy in current clinical practice and in clinical studies or clinical guidelines recommendations.In order to promote the standardized ICIs treatment,improve the benefits and overall survival of NSCLC patients,the Chinese Society of Clinical Oncology(CSCO)Immunotherapy Expert Committee,in collaboration with experts in the field,formulate the white paper on standardized continuous use of immunotherapy for NSCLC,aiming to reveal the status and issues of ICIs clinical use in different regions of China via a national questionnaire survey for oncologists,and form expert recommendations to provide guidance for standardized application of immunotherapy in hospitals at all levels nationwide.
Non-small cell lung cancerImmune checkpoint inhibitorStandardized immunotherapyWhite paper
万方数据
维普
